[en] OBJECTIVE: To evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in Belgium. METHODS: Effectiveness outcomes included improvement in 2005 global initiative for asthma (GINA) classification, physician-rated global evaluation of treatment effectiveness (GETE), quality of life (Juniper asthma-related quality of life (AQLQ) and European quality of life questionnaire 5 dimensions (EQ-5D)), and severe asthma exacerbations. Patients studied included both intent-to-treat and per-protocol populations. RESULTS: The sample (n=158) had a mean age of 48.17+/-17.18 years, and a slight majority were female (53.8%). Despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists, all patients experienced frequent symptoms and had exacerbations in the past year. At 16 weeks, >82% had good/excellent GETE (P values <0.001), >82% had an improvement in total AQLQ scores of > or =0.5 points (P<0.001), and >91% were severe exacerbation-free (P<0.001). At 52 weeks, >72% had a good/excellent GETE rating (P<0.001), >84% had improvements in total AQLQ score of > or =0.5 points (P<0.001), >56% had minimally important improvements in EQ-5D utility scores (P=0.012), and >65% were severe exacerbation-free (P<0.001). Significant reductions in healthcare utilization compared to the one year prior to treatment were noted. CONCLUSION: The PERSIST study shows better physician-rated effectiveness, greater improvements in quality of life, greater reductions in exacerbation rates, and greater reductions in healthcare utilization than previously reported in efficacy studies. Under real-life conditions, omalizumab is effective as add-on therapy in the treatment of patients with persistent severe allergic asthma.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Brusselle, G.
Michils, A.
Louis, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
Braman S.S. The global burden of asthma. Chest 130 1 Suppl. (2006 Jul) 4S-12S
Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31 1 (2008 Jan) 143-178
Cazzoletti L., Marcon A., Janson C., Corsico A., Jarvis D., Pin I., et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 120 6 (2007 Dec) 1360-1367
de Marco R., Cazzoletti L., Cerveri I., Corsico A., Bugiani M., Accordini S., et al. Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int Arch Allergy Immunol 138 3 (2005 Nov) 225-234
Humbert M., Beasley R., Ayres J., Slavin R., Hebert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 3 (2005 Mar) 309-316
Soler M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18 2 (2001 Aug) 254-261
Bousquet J., Wenzel S., Holgate S., Lumry W., Freeman P., and Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 125 4 (2004 Apr) 1378-1386
Buhl R., Hanf G., Soler M., Bensch G., Wolfe J., Everhard F., et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 20 5 (2002 Nov) 1088-1094
Niven R., Chung K.F., Panahloo Z., Blogg M., and Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 102 10 (2008 Oct) 1371-1378
Molimard M., de Blay F., Didier A., and Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 102 1 (2008 Jan) 71-76
Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 8 (2004 Oct 15) 836-844
Juniper E.F., Guyatt G.H., Epstein R.S., Ferrie P.J., Jaeschke R., and Hiller T.K. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47 2 (1992 Feb) 76-83
EQ-5D Value Sets. In: Szende A., Oppe M., and Devlin N. (Eds). Inventory, comparative review and user guide (2007), Springer, New York
Walters S.J., and Brazier J.E. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14 6 (2005 Aug) 1523-1532
Price D. The use of omalizumab in asthma. Prim Care Respir J 17 2 (2008 Jun) 62-72
Pilette C., Coppens N., Houssiau F.A., and Rodenstein D.O. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 120 4 (2007 Oct) 972-973
Bousquet J., Cabrera P., Berkman N., Buhl R., Holgate S., Wenzel S., et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60 3 (2005 Mar) 302-308
Lloyd A., Price D., and Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 16 1 (2007 Feb) 22-27
Benson K., and Hartz A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med 342 25 (2000 Jun 22) 1878-1886
Concato J., Shah N., and Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342 25 (2000 Jun 22) 1887-1892